EU Novel Food and CBD: What Retailers Actually Need to Know

Why CBD Edibles Are Treated Differently

The EU classifies foods with no significant history of consumption before May 1997 as "novel foods", governed by Regulation (EU) 2015/2283. Products in that category require pre-market authorisation before they can be lawfully sold as food.

The European Commission takes the position that cannabinoid extracts fall inside this definition. That is the root of the situation every retailer of ingestible CBD is currently operating in — and it applies to oils, capsules and edibles in a way it does not apply to products not sold for consumption.

Where the Assessments Currently Stand

EFSA, the European Food Safety Authority, assesses novel food applications on the Commission's behalf. In 2022 its panel concluded that it could not complete safety assessments of CBD because of significant data gaps, and evaluations were placed on hold pending further evidence. EFSA's own plain-language summary of that statement sets out the reasoning, and its novel food topic page tracks the current position.

The practical consequence is a long holding pattern: a large number of applications submitted, assessments paused, and enforcement left largely to individual member states in the meantime. That is why the legal reality for CBD edibles differs so much from one country to the next.

What This Means in Practice

• Enforcement is national, not uniform. A product sold without difficulty in one member state may be treated as an unauthorised novel food in another. Check your own market rather than assuming EU-wide consistency.
• Product format changes the analysis. Novel food rules attach to food. Products not presented for consumption sit under different rules — which is one reason the flower and resin side of the market has developed on a separate regulatory track from oils and edibles.
• Claims are a separate legal problem. Health claims on foods are governed by their own regime and are not something a COA can support. Describing what a product is remains safe; describing what it does for a body generally is not.

How to Reduce Your Exposure

Three things are within your control regardless of how the regulatory position develops.

Keep documentation with the stock. Batch-level certificates of analysis are the evidence base for any conversation with an inspector. Our guide to reading a COA covers what a complete one contains, and our testing process explains what ships with each batch.

Be conservative with claims. The commercial temptation is to say more than the evidence supports. Descriptive, factual product copy is both safer and, in a market crowded with overclaiming, more credible.

Know your own market's THC rule. Some markets set a percentage threshold; others require no detectable THC in the finished product. If you sell into the second kind, a compliant 0.2% product will not qualify — which is why our 0% THC range exists as a distinct line rather than a marketing angle.

What to Watch

The position is genuinely unsettled and worth rechecking rather than assuming. EFSA's novel food page is the primary source for assessment status; national food safety authorities publish their own enforcement positions, which in practice matter more day to day. Our country overview and legal guide summarise the landscape, but neither substitutes for checking your own jurisdiction.

This article is general information for retailers, not legal advice. If you are making stocking decisions with real money behind them, take advice specific to your market.